All In Biotech

Drug Trial Radar · NCT06818058

TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis

A Phase II Multicentric, Randomized, Double-blind, Placebo-controlled Study of TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis.

Last checked: Nov 19, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jan 20, 2025

Primary completion

Sep 1, 2026

Study completion Sep 30, 2026

Sponsor

Lead sponsor
Tarian PharmaIndustry
Sponsor type
Industry
First posted
Feb 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase II, multicentric, randomized, double-blind, placebo-controlled, parallel- group trial to confirm the good safaty profile and to explore the preventive effect of topically applied TAR-0520 gel on folliculitis developed in metastatic colorectal cancer (mCRC) patients treated with monoclonal anti-EGFR antibodies.

Conditions

  • EGFR Inhibitor-associated Rash

Interventions

  • Brimonidine tartrate GelDrug

    Once daily applications for 7 days

  • Placebo gel (no Brimonidine tartrate)Drug

    Once daily applications for 7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Treatment - emergent Advers Events (TEAEs)Time frame: At Baseline and then at Day 14, Day 28, Day 42 and Day 56 .

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Hopital Privé Jean Mermoz

    Lyon, France · Recruiting

  • Institut Paoli Calmette

    Marseille, France · Recruiting

  • Centre Antoine Lacassagne

    Nice, France · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.